Health DiagnosticsProcess AutomationDetectors, Sensors and MemsBiotechnologyConsumer GoodsPharmaceutical
Description
Repligen Corporation (‘Repligen’), a global life sciences company, develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.
The…
Analysis
Hope premium
Repligen Corporation carries what we call a hope premium: an average business trading at an ambitious price.
The price is expensive. You pay 70.4× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 23% yearly growth; analysts expect 20%. The price, in other words, assumes less than the experts do.
The trajectory is solid and the balance sheet is sturdy. The company scores 14/20 on our value-creation score: strong value creator.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202365
82
2023202420252026
All-time high
82
Jun 2026
All-time low
34
Mar 2026
Average rank
63
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
42
13
9
29
Price/Earnings
8
5
12
6
Price/Book
41
37
37
37
Dividend Yield
1
1
1
1
Value (overall)
12
6
1
5
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.